Q-omics provides the consensus-scored CATSPERD profile across patient tissues and cancer cell-line models. CATSPERD expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CATSPERD is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, CATSPERD RNA expression shows 8,509 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUSC as cancer lineages where CATSPERD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CATSPERD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CATSPERD survival associations across molecular data types. CATSPERD RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CATSPERD RNA expression–survival associations across cancer types. High CATSPERD expression shows unfavorable associations in ACC, KIRC, KICH, OV and THCA, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CATSPERD RNA expression.
This table summarizes CATSPERD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CATSPERD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CATSPERD shows lower tumor expression in LUSC, LUAD, THCA, UCEC and KIRC and higher tumor expression in CHOL. The LUSC box plot shows higher CATSPERD RNA expression in normal versus tumor tissue (log2 FC = −1.531, t-test p < 0.001).
This table shows molecular features associated with CATSPERD in patient tissues and cancer cell lines. In patient samples, CATSPERD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CATSPERD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
